MedTrace Logo

Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS

NCT07009691 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-06-08

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are:

Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME/CFS?

Can HRV be used to predict who will benefit from treatment with hydrogen water?

Conditions

  • Chronic Fatigue Syndrome

Interventions

DIETARY_SUPPLEMENT

Hydrogen water which is prepared from an OTC supplement.

The intervention is hydrogen water which is prepared from an OTC supplement. It involves measurement of heart rate variability.

Sponsors & Collaborators

Principal Investigators

  • Fred Friedberg, PhD · Stony Brook University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-09
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07009691 on ClinicalTrials.gov